Article Sidebar
Published:
Nov 20, 2023Keywords:
Article Details
On acceptance, the copyright of a manuscript will be vested in the journal and publisher. Articles published in Afrimedic journal are distributed under the terms of the Creative Commons Attribution License which allows for unrestricted use, distribution and reproduction in any medium, for any non-commercial purpose, subject to proper citation of the original work.
References
Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
van Der Hage JA, van De Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C & Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. Journal of Clinical Oncology 2001; 19: 4224–4237.
Gianni L, Baselga J, Eirmann W, et al. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol. 2005;23:7.
Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–4174.
Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): effect of primary systemic therapy. Proc Am Soc Clin Oncol. 2002;21:34.
EBCTCG 1992. Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1–15.
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 1998;16: 2672–2685.
Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483–2493.
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN et al. PhaseII trial of taxol, an active drug in the treatment of metastatic breast cancer. Journal of the National Cancer Institute 1991; 83 1797–1805.
Moliterni A, Tarenzi E, Capri G, Terenziani M, Bertuzzi A, Grasselli G et al.Pilot study of primary chemotherapy with doxorubicin pluspaclitaxel in women with locally advanced or operable breast cancer. Seminars in Oncology 1997; 24 S17-10–S17-14.
Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N et al. Fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvanttherapy in patients with operable breast cancer. Journal ofClinical Oncology 1999; 17: 3412–3417.
Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. "Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis". The Journal of Rheumatology 1991; 18 (2): 188–94.
Lohrmann HP (1984). "The problem of permanent bone marrow damage after cytotoxic drug treatment". Oncology 1984; 41 (3): 180–4.
Singh JA, Hossain A, Kotb A, Wells G. "Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis". BMC Medicine 2016; 14 (1): 137.
Twohig KJ, Matthay RA. "Pulmonary effects of cytotoxic agents other than bleomycin". Clinics in Chest Medicine 1990; 11 (1): 31–54.
Malik SW, Myers JL, DeRemee RA, Specks U. "Lung toxicity associated with cyclophosphamide use. Two distinct patterns". American Journal of Respiratory and Critical Care Medicine 1996; 154 (6 Pt 1): 1851–6.
Chittipolu Ajaykumar (December 2nd 2020). Overview on the Side Effects of Doxorubicin [Online First], IntechOpen, DOI: 10.5772/intechopen.94896. Available from: https://www.intechopen.com/online-first/overview-on-the-side-effects-of-doxorubicin
Rossi, S, ed. Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
Brayfield, A, ed. "Fluorouracil: Martindale: The Complete Drug Reference". Medicines Complete. London, UK: Pharmaceutical Press. Retrieved 14 August 2017.
Andreopoulou E., Schweber S.J., Sparano J.A., McDaid H.M. Therapies for triple negative breast cancer. Expert Opin. Pharmacother. 2015;16:983–998.
Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010;363:1938–1948.
Santonja A., Sanchez-Muñoz A., Lluch A., Chica-Parrado M.R., Albanell J., Chacon J.I., Antolín S., Jerez J.M., De La Haba J., De Luque V., et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9:26406–26416.
Egwuonwu OA. Efficacy of neoadjuvant chemotherapy for down staging locally advanced pre-menopausal breast cancer in NAUTH, Nnewi. FMCS Dissertation, 2011.
Chintamani, Singhal V, Singh JP, Lyall A, Saxena S, Bansal A. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? -A prospective clinical study. BMC Cancer. 2004; 4: 48.
Moon YW, Rho SY, Jeung HC, Yang WI, Suh CO, Chung HC, et al. Neoadjuvant chemotherapy with infusional 5FU, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response Predicts good prognosis. Ann Oncol 2005; 16:1778-1785.
Broet P, Scholl SM, de la Rochefordiere A, Fourquet A,Moreau T, De Rycke Y et al. Short and long-term effects on survival in breast cancer patients treated by primarychemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 1999; 58: 151–156.
van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224–4237.
Clegg-Lamptey JNA, Hodasi WM. A study of breast cancer in Korle Bu Teaching Hospital: assessing the impact of health education. Ghana Med J. 2007;41(2):72–77.
Mieog JSD, van der Hage JA and van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. British Journal of Surgery 2007; 94: 1189–1200.
Main Article Content
Tolerace And Toxicity To Anthracycline Based Neoadjuvant Chemotherapy In Premenopausal Women With Breast Cancer
Abstract
Background: Cytotoxic drugs play an important role in the management of breast cancer particularly in pre-menopausal patients and patients with triple negative breast cancer (TNBC).The adverse reactions to chemotherapeutic drugs are wide and varied. These adverse reactions to chemotherapy drugs could be haematologic and non-haematologic.
Objectives: The study aims to evaluate the toxicity and tolerance of cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) combination on pre-menopausal women with breast cancer.
Materials and methods: A Doxorubicin containing regimen (CAF) consisting of cyclophosphamide 500 mg/m2, Doxorubicin 50 mg/m2, and 5-Fluorouracil 500 mg/m2 all were given on day one. During the course of the cytotoxic drugs, all the side effects both haematological and non-haematological were recorded. The data collected were analyzed using the SPSS statistical software version 23.0. (Statistical Package for Social Sciences SPSS Inc.).
Results: Forty-nine patients were recruited with age range 24 to 54 (40.92±7.98) years. Out of 49 patients, 8(16.3%) developed anaemia, 2(4.1%) leucopenia and 3(6.1%) mild thrombocytopenia during neoadjuvant chemotherapy. The majority of the patients, 41 (83.7%), did not produce significant haematologic side effects. Out of a total of 49 patients, 47 (95.9%) developed atleast one non-haematologic side effect during neoadjuvant chemotherapy. The most common side effects were: vomiting, nausea and body weakness at the frequencies of 29 (59.2%), 28 (57.1%) and 24 (50.0%), respectively.
Conclusion: The study demonstrated that neoadjuvant CAF chemotherapy was very tolerable by our patients with only minimal haematological and non-haematological toxicities. The recorded toxicities were readily managed by simple measures without need for admission.
